ASCO 2024: ADELIS participates in groundbreaking study predicting Immunotherapy resistance with cell-free DNA analysis
Our findings highlight that cell-free DNA fragments can predict early progression in patients with advanced or metastatic cancer undergoing immune-checkpoint inhibition.
Standard PD-L1 testing identifies 60% of newly diagnosed patients as eligible for immuno-oncology treatments. However, 20% of eligible patients are missed, and among those identified, 50% do not respond to treatment, with about 30% experiencing severe adverse effects.
The SCHISM study, presented at ASCO 2024, is addressing this critical issue by analyzing circulating DNA fragments. Intermediate data from this groundbreaking study were showcased at the conference.
A key factor in the project’s success is the size profile analysis of circulating DNA, enabled by our BIABOOSTER technology.